Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab.
Blood tests detecting cancer DNA fragments predict relapse risk in triple-negative breast cancer, helping doctors tailor follow-up treatment intensity.
This study evaluates a tumor-informed molecular residual disease assay using ctDNA in early TNBC, demonstrating strong prognostic association with distant recurrence. The findings support ctDNA MRD as a clinically actionable biomarker to guide escalation or de-escalation of adjuvant therapy in TNBC.
What the study was
- Study design
- Clinical validation study (tumor-informed ctDNA MRD assay)
- Population
- Early-stage triple-negative breast cancer patients
- Category
- Early Detection
- Maturity
- Potentially Practice-Changing
- Journal
- JCO precision oncology
Why it surfaced
Validated ctDNA MRD assay in early TNBC—one of the highest-need breast cancer subtypes—with direct implications for adjuvant treatment decision-making.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.